Revenue growth early-to-mid teens in FY27
Management expects consolidated revenue growth in the early-to-mid teens for FY27, excluding the previously destocked on-patent commercial product.
PIRAMALPHARMA / guidance tracker
Keep management guidance in view.
Piramal Pharma · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
EBITDA to grow faster than revenue in FY27
EBITDA is expected to grow faster than revenue, supported by operating leverage from higher scale.
Capex of $120-135 million for FY27
Capital expenditure for FY27 is guided at $120-135 million, primarily for Lexington expansion and other growth projects.
Net debt to EBITDA to remain around 3.6x in FY27
Net debt to EBITDA is expected to remain range-bound at about 3.6x for FY27, with long-term target of 1x.